Private label Zantac 75 marketable December 1998 under Glaxo/Novopharm ruling.
This article was originally published in The Tan Sheet
PRIVATE LABEL OTC RANITIDINE WILL BE MARKETABLE IN DECEMBER 1998 as a result of Novapharm's victory in the Form 1 ranitidine patent case with Glaxo Wellcome. Raleigh, N.C. federal court Judge Terrence Boyle ruled July 5 that Novopharm has established that it is possible to manufacture Form 1 ranitidine without infringing Glaxo's patent for Form 2 of the anti-ulcer agent Zantac.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC